ATOSSA THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
ATOS$2.13+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(amounts in thousands, except share and per share data)
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses | ||
| Research and development | $17,334 | $15,083 |
| General and administrative | 14,043 | 12,608 |
| Total operating expenses | 31,377 | 27,691 |
| Operating loss | (31,377) | (27,691) |
| Impairment charge on investment in equity securities | (2,990) | — |
| Interest income | 4,343 | 877 |
| Other expense, net | (70) | (146) |
| Loss before income taxes | (30,094) | (26,960) |
| Income tax benefit | — | — |
| Net loss | (30,094) | (26,960) |
| Net loss per share of common stock - basic and diluted | $(0.24) | $(0.21) |
| Weighted average shares outstanding used to compute net loss per share - basic and diluted | 126,081,602 | 126,624,110 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.